Evidence map›Paper›PMID 38956156›Full record

ArticleScientific reports2024

System-agnostic prediction of pharmaceutical excipient miscibility via computing-as-a-service and experimental validation.

Georgios S E Antipas, Regina Reul, Kristin Voges, Samuel O Kyeremateng, Nikolaos A Ntallis, Konstantinos T Karalis, Lukasz Miroslaw

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Georgios S E AntipasMolecular Modelling Laboratory, Bahnhofplatz, 6300, Zug, Switzerland. gantipas@mmlpi.ch.
Regina ReulAbbVie Deutschland GmbH & Co. KG, Development Sciences, 67061, Ludwigshafen, Germany.
Kristin VogesAbbVie Deutschland GmbH & Co. KG, Development Sciences, 67061, Ludwigshafen, Germany.
Samuel O KyerematengAbbVie Deutschland GmbH & Co. KG, Development Sciences, 67061, Ludwigshafen, Germany. samuel.kyeremateng@abbvie.com.
Nikolaos A NtallisMolecular Modelling Laboratory, Bahnhofplatz, 6300, Zug, Switzerland.
Konstantinos T KaralisMolecular Modelling Laboratory, Bahnhofplatz, 6300, Zug, Switzerland.
Lukasz MiroslawAzure High Performance Computing and Artificial Intelligence, Microsoft Switzerland, The Circle 02, 8058, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We applied computing-as-a-service to the unattended system-agnostic miscibility prediction of the pharmaceutical surfactants, Vitamin E TPGS and Tween 80, with Copovidone VA64 polymer at temperature relevant for the pharmaceutical hot melt extrusion process. The computations were performed in lieu of running exhaustive hot melt extrusion experiments to identify surfactant-polymer miscibility limits. The computing scheme involved a massively parallelized architecture for molecular dynamics and free energy perturbation from which binodal, spinodal, and mechanical mixture critical points were detected on molar Gibbs free energy profiles at 180 °C. We established tight agreement between the computed stability (miscibility) limits of 9.0 and 10.0 wt% vs. the experimental 7 and 9 wt% for the Vitamin E TPGS and Tween 80 systems, respectively, and identified different destabilizing mechanisms applicable to each system. This paradigm supports that computational stability prediction may serve as a physically meaningful, resource-efficient, and operationally sensible digital twin to experimental screening tests of pharmaceutical systems. This approach is also relevant to amorphous solid dispersion drug delivery systems, as it can identify critical stability points of active pharmaceutical ingredient/excipient mixtures.

Indexed as

ExcipientsPolysorbatesHot Melt Extrusion TechnologyMolecular Dynamics SimulationPyrrolidinesSurface-Active AgentsThermodynamicsVinyl CompoundsVitamin EExcipientsPolysorbatespoly(vinylpyrrolidone-co-vinyl-acetate)PyrrolidinesSurface-Active AgentsVinyl CompoundsVitamin EActive pharmaceutical ingredientAmorphous phase separationAmorphous solid dispersionChemical potentialComputing as a serviceExcipientMolar free energyMolecular dynamicsPhysical stabilityPlaceboRecrystallizationSolubility limitSurfactant

Identifiers

PMID38956156
PMCPMC11219749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.